Latest News and Press Releases

Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype BASKING RIDGE, NJ, March 25, 2022 (GLOBE NEWSWIRE) -- via...

- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference - - Company plans to initiate Phase 3 study in second quarter of 2022 - BASKING RIDGE, NJ, Feb....

Virtual Conference on January 10-13, 2022 BASKING RIDGE, NJ, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR),...

Call to be held on Monday, November 22nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...

Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End  BASKING RIDGE, NJ, Nov. 15, 2021 (GLOBE NEWSWIRE) --...

Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million Basking Ridge, NJ, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or...

Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...

Basking Ridge, NJ, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...

Basking Ridge, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...

Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG™ TMB-001 (topical isotretinoin) Company planning for end-of-Phase 2 meeting with FDA in the...